{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+equivalent&page=20", "query": { "intervention": "Placebo equivalent", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 843, "total_pages": 85, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+equivalent&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+equivalent&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-14T12:22:00.768Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00267007", "title": "A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Peripheral Neuropathy, Chemotherapy-induced" ], "interventions": [ { "name": "PROCRIT 40,000 IU QW", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2006-06", "completion_date": "2008-08", "has_results": true, "last_update_posted_date": "2014-06-04", "last_synced_at": "2026-11-14T12:22:00.768Z", "location_count": 28, "location_summary": "Mobile, Alabama • Little Rock, Arkansas • Alhambra, California + 25 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Alhambra", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00267007" }, { "nct_id": "NCT04265534", "title": "KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer", "Non-squamous Non-small-cell Lung Cancer", "Non-Squamous Non-Small Cell Neoplasm of Lung", "KEAP1 Gene Mutation", "NRF2 Gene Mutation", "NFE2L2 Gene Mutation" ], "interventions": [ { "name": "Telaglenastat", "type": "DRUG" }, { "name": "Carboplatin Chemotherapy", "type": "DRUG" }, { "name": "Pemetrexed Chemotherapy", "type": "DRUG" }, { "name": "Pembrolizumab Immunotherapy", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Folic acid 400 -1000 μg", "type": "DIETARY_SUPPLEMENT" }, { "name": "Vitamin B12 1000 μg", "type": "DIETARY_SUPPLEMENT" }, { "name": "Dexamethasone 4 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "DIETARY_SUPPLEMENT" ], "sponsor": "Calithera Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2020-07-24", "completion_date": "2022-02-09", "has_results": false, "last_update_posted_date": "2022-09-21", "last_synced_at": "2026-11-14T12:22:00.768Z", "location_count": 102, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Yuma, Arizona + 86 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Yuma", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04265534" }, { "nct_id": "NCT02970162", "title": "Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lambert-Eaton Myasthenic Syndrome" ], "interventions": [ { "name": "Amifampridine Phosphate", "type": "DRUG" }, { "name": "Placebo Oral Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Catalyst Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2016-11", "completion_date": "2017-10", "has_results": true, "last_update_posted_date": "2018-12-24", "last_synced_at": "2026-11-14T12:22:00.768Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02970162" }, { "nct_id": "NCT01180660", "title": "IV Lidocaine on Postoperative Pain and QOR on Morbid Obese Patients Undergoing Bypass Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pain", "Obesity" ], "interventions": [ { "name": "Lidocaine Infusion", "type": "DRUG" }, { "name": "Normal Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 51, "start_date": "2010-06", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2014-08-07", "last_synced_at": "2026-11-14T12:22:00.768Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01180660" }, { "nct_id": "NCT04933240", "title": "Tamoxifen Versus Estradiol for Unscheduled Bleeding in Etonogestrel Implant Users, a Randomized Pilot Trial", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Vaginal Bleeding" ], "interventions": [ { "name": "Tamoxifen Citrate 10Mg Tab", "type": "DRUG" }, { "name": "Estradiol", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "15 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "15 Years to 45 Years · Female only" }, "enrollment_count": 0, "start_date": "2022-05", "completion_date": "2024-12", "has_results": false, "last_update_posted_date": "2022-06-03", "last_synced_at": "2026-11-14T12:22:00.768Z", "location_count": 2, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04933240" }, { "nct_id": "NCT02426918", "title": "Study of Debio 1450 for Bacterial Skin Infections", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bacterial Infections" ], "interventions": [ { "name": "Debio 1450 IV", "type": "DRUG" }, { "name": "Debio 1450 Oral", "type": "DRUG" }, { "name": "Linezolid", "type": "DRUG" }, { "name": "Debio 1450 Oral Placebo", "type": "DRUG" }, { "name": "Linezolid Placebo", "type": "DRUG" }, { "name": "Vancomycin IV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Debiopharm International SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 330, "start_date": "2015-05", "completion_date": "2016-09", "has_results": true, "last_update_posted_date": "2019-11-13", "last_synced_at": "2026-11-14T12:22:00.768Z", "location_count": 22, "location_summary": "Anaheim, California • Buena Park, California • Chula Vista, California + 17 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Anaheim", "state": "California" }, { "city": "Buena Park", "state": "California" }, { "city": "Chula Vista", "state": "California" }, { "city": "La Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02426918" }, { "nct_id": "NCT04819230", "title": "A Cognitive Bias Modification RCT for Aggression", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Intermittent Explosive Disorder" ], "interventions": [ { "name": "Cognitive Bias Modification", "type": "BEHAVIORAL" }, { "name": "Cognitive Bias Control", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Temple University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 45, "start_date": "2021-05", "completion_date": "2023-06", "has_results": false, "last_update_posted_date": "2021-03-26", "last_synced_at": "2026-11-14T12:22:00.768Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04819230" }, { "nct_id": "NCT01671800", "title": "Study to Assess the Efficacy of Botulinum Toxin B (Myobloc) for the Treatment of Prosthesis-associated Sweating", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hyperhidrosis" ], "interventions": [ { "name": "Botulinum Type B", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Henry M. Jackson Foundation for the Advancement of Military Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 20, "start_date": "2008-09", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2013-01-10", "last_synced_at": "2026-11-14T12:22:00.768Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01671800" }, { "nct_id": "NCT05664477", "title": "PhytoSERM to Prevent Menopause Associated Decline in Brain Metabolism and Cognition", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Menopause", "Cognitive Change", "Brain Disorder, Metabolic" ], "interventions": [ { "name": "PhytoSERM", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG" ], "sponsor": "Roberta Brinton", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "45 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "45 Years to 60 Years" }, "enrollment_count": 100, "start_date": "2024-01-10", "completion_date": "2027-01-31", "has_results": false, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-11-14T12:22:00.768Z", "location_count": 2, "location_summary": "Tucson, Arizona • New York, New York", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05664477" }, { "nct_id": "NCT03005067", "title": "To Evaluate the Efficacy and Safety of 1146A Nasal Spray in Adult Participants With Symptoms of Common Cold", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Common Cold" ], "interventions": [ { "name": "Carbomer 980 (1146A)", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 171, "start_date": "2016-12-29", "completion_date": "2017-06-07", "has_results": true, "last_update_posted_date": "2018-06-19", "last_synced_at": "2026-11-14T12:22:00.768Z", "location_count": 24, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Vista", "state": "California" }, { "city": "Centennial", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03005067" } ] }